Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Strides Shasun Concedes Acquisitions Harder To Swallow Than Expected As Earnings Disappoint

Executive Summary

Arun Kumar, managing director of leading Indian pharmaceutical company Strides Shasun, was hailed as the man with the Midas touch when he sold the company’s injectable-medicine unit to Mylan Inc three years ago for a hefty $1.6bn. But his business-savvy reputation has taken a bit of a knock with Strides conceding the digestion of some recent acquisitions is taking longer than expected after the firm reported earnings which sent its shares tumbling.

You may also be interested in...



Strides’ Founder Resumes Charge After Dismal Q4 Earnings

Strides Shasun founder Arun Kumar has moved back into the driver’s seat to focus on “course correction” after the Indian drug maker racked up an unexpected quarterly loss that triggered a massive share selloff.

Strides Shasun Expands Australia Base With Amneal Deal

Indian drug firm Strides Shasun has acquired the Australian unit of Amneal Pharmaceuticals, extending its customer footprint as it sets sights on becoming the leading player in the Australian generics market.

Top US Court Lifts Discovery Stay On Price-Fixing

The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel